New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
08:03 EDTIG, IPXLIGI Laboratories completes seventh ANDA filing under joint agreement with Impax
IGI Laboratories (IG) announced it has submitted its seventh abbreviated new drug application in 2014 to the FDA. The seventh ANDA submission was in connection with an existing development, supply and marketing agreement with Impax Laboratories (IPXL). The agreement designates IGI Laboratories as the developer, manufacturer, and owner of a generic topical pharmaceutical drug product, which will be licensed, marketed and distributed in the United States by Global Pharmaceuticals, Impax's generics division. In accordance with the agreement, Impax is required to pay IGI when certain milestones are met related to the filing and approval of the associated ANDA.
News For IG;IPXL From The Last 14 Days
Check below for free stories on IG;IPXL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
12:30 EDTIPXLImpax downgraded to Market Perform from Outperform at Cowen
Subscribe for More Information
08:18 EDTIPXLImpax announces FDA performs inspection on Taiwan facility
Impax announced that the FDA performed a general GMP inspection and a Pre-Approval Inspection for RYTARYTM at the company's Taiwan manufacturing facility from July 21 to July 26. At the conclusion of the inspection, the FDA issued a Form 483 with ten inspectional observations. The Taiwan facility was approved for product manufacturing by the FDA in September 2009 and by Taiwan FDA in July 2010. The facility currently manufactures 12 products for distribution in the United States. The FDA did not provide any status or classification to these observations and will wait until they have received and reviewed the company's response to provide this information. The Ccmpany has also not been informed by the FDA of the impact this Form 483 may have on RYTARY's October 9 review date under the Prescription Drug User Fee Act.
July 28, 2014
09:06 EDTIGIGI Laboratories weakness a buying opportunity, says Craig-Hallum
Craig-Hallum recommends buying IGI Laboratories and is confident in the growth opportunities and expected ANDA approvals. Shares are Buy rated.
July 24, 2014
16:24 EDTIGIGI Laboratories reports Q2 EPS (1c), consensus 0c
Subscribe for More Information
16:22 EDTIGIGI Laboratories director Damian Finio resigns
IGI Laboratories has accepted Damian Finio's resignation from its Board of Directors effective August 11. Mr. Finio has accepted a senior level finance position at a pharmaceutical company, and will be unable to continue in his role as Director. The company has begun a search to replace Mr. Finio on its Board.
July 16, 2014
11:35 EDTIPXLLannett announces inquiry received from Connecticut Attorney General
Subscribe for More Information
09:11 EDTIPXLLannett risk has increased on competitor probe, says Roth Capital
Subscribe for More Information
July 15, 2014
17:10 EDTIPXLImpax receives subpoena related to digoxin sales
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use